X4 Pharmaceuticals ( (XFOR) ) has shared an announcement.
X4 Pharmaceuticals has announced promising results from its Phase 2 trial of mavorixafor, an oral treatment for chronic neutropenia. The trial demonstrated that mavorixafor effectively increased mean absolute neutrophil counts (ANC) and allowed for reduced dosing of G-CSF while maintaining normal ANC levels. The findings, including enhanced neutrophil functionality, bolster confidence in the ongoing Phase 3 4WARD trial, offering hope for improved treatments for those with chronic neutropenia.
Find detailed analytics on XFOR stock on TipRanks’ Stock Analysis page.